Iovance Reports Phase 2 Melanoma Data With 62.5% ORR
Final Phase 2 data showed a 62.5% confirmed overall response rate and 29.2% complete response rate with one-time lifileucel plus pembrolizumab in frontline advanced melanoma. Median overall survival was not reached at 50.9 months’ median follow-up.